Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
about
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancerArginine methylation controls growth regulation by E2F-1The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal MetastasisInflammation meets cancer, with NF-κB as the matchmakerOptimizing adjuvant therapy and survivorship care of stage III colon cancer.Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysisAutocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studiesContinuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerA new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerThe utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.TLR agonists: our best frenemy in cancer immunotherapyRandomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.Biomarkers in precision therapy in colorectal cancer.Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol.Current opinion on optimal treatment for colorectal cancer.A systematic review of outcome reporting in colorectal cancer surgery.COX-2 inhibitors in prostate cancer treatment--hold your horses?Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.Aspirin therapy for cancer: it is never too late.RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.Will an aspirin a day keep the colorectal cancer away?
P2860
Q21144952-25BAA775-2D25-458C-AEF0-42629E0BB5CDQ24305116-3DDE36BD-C87D-4486-B837-1FDCA9A7E698Q26783022-C446919E-66C4-4D6A-9CE5-C89AF66F6C81Q29620242-3D9AE483-05ED-4613-BCF2-D483EB52689DQ30249616-5B214338-5B6D-44E1-B28B-87BDAF06610CQ30521133-EBE5F438-E7B1-4D76-A492-305B8F416CC6Q34048230-4D0EEAD9-6D6F-4D25-9732-EA9AD055FBD4Q34140169-1E12B16E-784C-4587-B8A7-0592091A1122Q34658238-097E730A-5C3B-4A9F-9291-B18C24D3D362Q35034703-C07E2077-2C1F-46FE-8D41-DBF1E53CCF19Q35626744-FA03505B-1898-4D82-AA31-595443A0A481Q35735849-B0D2A775-B620-4AE0-B580-BA6DA3EF1C2FQ35996689-062C57B0-B105-49F6-A0C9-BE874BB8C8E7Q36279825-0D1873E5-EA30-470C-885E-74AECED01FFFQ36656389-2F9A54C1-D3BC-43F9-975B-DFC2441A13B0Q36850457-2FB99F9F-C470-4F31-BBAD-B5A83D83DF1EQ36961451-63BDD42C-8923-4E02-BC38-462B6558C46CQ37367984-EB0C98AA-4712-4EE9-A96E-F57C6795FF62Q37609130-F3017A8D-DB33-4F40-AB39-C0197FB6F7E9Q37662128-6F06B318-C375-4679-BCC0-E0AC266A9D36Q37879601-38671BED-7D5D-4764-AF3E-7BC1159D635EQ38101612-D2EC90A7-DA6C-4799-A3C3-AAB54741FF15Q38127433-C36164B7-BC32-4465-B96A-E93179E092EBQ42140641-E4F374F1-67E1-4B18-A816-D5C07AB6340CQ42935094-E0FA4847-CF71-447C-B46E-92BF6CC0B6F0Q42958488-1559CE6F-F248-4510-9C6B-64123ACEEEF0Q43215154-6B949589-E859-4C5D-B935-00530FDA6E47Q51604439-1250271C-F9AD-4DC6-821A-197C69D5E81CQ53786874-A8DF443F-DC5F-4A2E-B42B-C7E40EA753EAQ57258032-7C8D7AF6-EA56-49A8-84C7-095D5D931244
P2860
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase III randomized trial ass ...... l results of the VICTOR trial.
@en
Phase III randomized trial ass ...... l results of the VICTOR trial.
@nl
type
label
Phase III randomized trial ass ...... l results of the VICTOR trial.
@en
Phase III randomized trial ass ...... l results of the VICTOR trial.
@nl
prefLabel
Phase III randomized trial ass ...... l results of the VICTOR trial.
@en
Phase III randomized trial ass ...... l results of the VICTOR trial.
@nl
P2093
P356
P1476
Phase III randomized trial ass ...... l results of the VICTOR trial.
@en
P2093
Bryan Warren
Christopher C McConkey
Claire Iveson
David J Kerr
Elaine C Johnstone
Justine L Smith
Michael J Langman
Patrick Julier
Rachel S Midgley
Simon A Grumett
P304
P356
10.1200/JCO.2010.29.6244
P407
P50
P577
2010-09-13T00:00:00Z